Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Kymera Therapeutics

Kymera Therapeutics

Kymera Therapeutics is a Cambridge, Massachusetts-based biotechnology company specialized in the field of targeted protein degradation.

Kymera Therapeutics is a clinical stage biopharmaceutical company that is developing novel protein degrader therapeutics for treating disease in effective new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of removing them from the body. Kymera Therapeutics is driven to invent transformative medicines for a broad variety of diseases where traditional drug modalities have failed to adequately unlock the appropriate biological solution.

The company is pioneering a transformative new modality, “targeted protein degradation” (TPD), with the capability to pursue targets long considered undruggable and to treat disease in new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to better the lives of patients with serious diseases.

Its team has developed a proprietary drug discovery engine, Pegasus, to allow the design of highly selective, small molecule protein degraders with potent activity against a wide range of disease indications. The company is committed to selecting targets with the widest possible impact across multiple disease indications with unmet medical need to realize the full potential of TPD.

Timeline

March 12, 2020
Kymera Therapeutics raises a $102,000,000 series C round from Biotechnology Value Fund.
November 13, 2018
Kymera Therapeutics raises a $65,000,000 series B round from 6 Dimensions Capital.
October 30, 2017
Kymera Therapeutics raises a $30,000,000 series A round.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 21, 2021
BioSpace
Data presented at the 16th ICML Meeting demonstrate KT-413's potent antitumor activity as a monotherapy compared to a clinically active IRAK4 kinase inhibitor or a latest generation IMiD in MYD88-mutant mouse xenograft model.
BioSpace
June 9, 2021
BioSpace
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that an abstract featuring new preclinical data for its IRAKIMiD degrader KT-413 has been selected for oral presentation at the 16th Annual International Conference.
BioSpace
May 10, 2021
BioSpace
New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory models KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK4 degrader for the treatment of immune-inflammatory diseases, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and potentially others
BioSpace
May 5, 2021
BioSpace
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology.
BioSpace
April 19, 2021
BioSpace
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ) has named Kymera Therapeutics to its 2021 Best Places to Work, an exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.